A New York, USA-based supermarket chain, Wegmans Food Markets, has entered the generic drug discount price war started by Wal-Mart, the world's largest retailer, with the latter's recent launch of a $4 charge for 30 days' supply of selected generics (Marketletters October 2 and 30).
The Wegmans offer means that, for almost 100 generic drugs in about 200 dosages, 90-day prescriptions will be supplied at $11.99, a saving of over half to customers in some cases. John Carlo, Wegmans' director of managed care, told local reporters that "we have compiled a list of maintenance drugs which are frequently prescribed for our customers." He added: "it's likely the list will evolve over time with possibly more drugs or dosages added." The firm operates 50 stores in New York State, 11 in Pennsylvania, seven in New Jersey, two in Virginia and one in Maryland.
Meanwhile, Wal-Mart has announced a third wave for its $4 generic drugs offers, expanding the US states where its stores apply the promotion to Alabama, Georgia, Iowa, Kansas, Maryland, Michigan, Mississippi, Missouri, New Hampshire, Ohio, South Dakota and Virginia. The move means that the discount drug offer is now available in a majority of US states and Wal-Mart has stated its intention of covering additional areas as soon as possible, according to local reports.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze